Rodriguez-Martinez CE, et al. - By developing a decision-analysis model, researchers assessed the cost-effectiveness of inhaled corticosteroids (ICS) in addition to systemic corticosteroids (SCs) (ICS + SCs) vs standard therapy with SCs for treating pediatric patients with acute asthma exacerbations in this investigation performed from the perspective of the national healthcare system in Colombia. From a systematic review of the literature, they obtained effectiveness parameters. Avoidance of hospital admission was the main outcome. According to the findings, lower total costs (US$88.76 vs US$97.71 average cost per patient) and a lower chance of hospital admission (0.9060 vs 0.9000) were observed in relation to therapy with ICS + SCs vs standard therapy with SCs, and thus the former treatment strategy is preferred.